Safety, Pharmacokinetics, and Sex Hormone Suppression of LY01021 versus Relugolix: A Single- and Multiple-Dose Escalation Study.
LY01021 is a novel oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of various sex hormone-dependent disorders. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), …
Neutrophil extracellular traps in gynecological disease: pathogenic mechanisms and therapeutic opportunities.
Gynecologic disorders, including infections, sterile inflammatory diseases, endocrine abnormalities, and malignancies, share a common signature of dysregulated immunity within a uniquely hormone-responsive reproductive tract. Neutrophil extracellular traps (NETs) are increasingly …
Looking at endometriosis-diagnosis and disease mechanisms through a mechanical lens.
Endometriosis is a chronic gynecological disorder marked by the growth of endometrial-like tissue outside the uterus, often resulting in pain and infertility and affecting overall quality of life. Despite its …
Ozone Pharmaceuticals Hosts Women’s Health Forum ‘4 Her’ In Delhi, Draws 100 Gynecologists With Dr. Kiran Bedi And Dr. Nikita Trehan - Content Media Solution
Ozone Pharmaceuticals Hosts Women’s Health Forum ‘4 Her’ In Delhi, Draws 100 Gynecologists With Dr. Kiran Bedi And Dr. Nikita Trehan Content Media Solution
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace